| Market Capitalization (Millions $) |
175 |
| Shares
Outstanding (Millions) |
43 |
| Employees |
22 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-46 |
| Cash Flow (TTM) (Millions $) |
3 |
| Capital Exp. (TTM) (Millions $) |
0 |
Checkpoint Therapeutics Inc
Checkpoint Therapeutics Inc. is a clinical stage biopharmaceutical company that focuses on the development of immunotherapy treatments for cancer. The company was founded in 2014 and is headquartered in New York City, USA. Checkpoint Therapeutics is a publicly traded company on the NASDAQ stock exchange with the ticker symbol "CKPT".
The company's primary focus is to develop treatments that enable the immune system to recognize and attack cancer cells by blocking two specific proteins: PD-L1 and VISTA. These proteins are frequently found on the surface of cancer cells, and they help the cancer cells evade detection by the body's immune system. If the immune system can't recognize the cancer cells, it can't attack them effectively, and the cancer cells continue to grow and spread.
Checkpoint Therapeutics is developing two lead drug candidates: CK-301 and CK-10 CK-301 is an anti-PD-L1 antibody that is entering Phase 3 clinical trials for non-small cell lung cancer, and CK-101 is an anti-PD-L1/VISTA bispecific antibody that is currently in Phase 1b clinical trials for advanced solid tumors.
In addition to its lead candidates, Checkpoint Therapeutics has a pipeline of additional immunotherapy treatments in preclinical development, including a bispecific antibody targeting PD-1 and LAG-3, and an agonistic antibody targeting CD40.
The company has a partnership with TG Therapeutics, Inc. for the development and commercialization of CK-301 in combination with TG's anti-CD20 monoclonal antibody, ublituximab, for the treatment of lymphoma.
Overall, Checkpoint Therapeutics' mission is to develop innovative immunotherapy treatments that can improve outcomes for patients with cancer. The company's emphasis on targeting PD-L1 and VISTA makes it well-positioned to continue making progress in the fight against cancer.
Company Address: 95 Sawyer Road Waltham 2453 MA
Company Phone Number: 652-4500 Stock Exchange / Ticker: NASDAQ CKPT
|
1.21% 